

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
	<title>Medicines regulatory news feed</title>
	<link>http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&amp;nodeId=100806</link>
 

<item>
<title>Authorised signatories for medicines advertising</title>
<pubDate>Mon, 21 May 2012 14:42:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152737 </link>
	 <description><![CDATA[Clause 14.4 of the ABPI Code of Practice for the Pharmaceutical Industry requires companies to submit details of persons nominated to certify advertising materials to the Prescription Medicines Code of Practice Authority and to the MHRA Advertising Standards Unit.  The MHRA has set up a dedicated mailbox to facilitate compliance with this obligation.<br/> ]]></description>
	 </item>
 

<item>
<title>Training to support the expansion of the BROMI notification scheme</title>
<pubDate>Mon, 21 May 2012 14:40:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152733 </link>
	 <description><![CDATA[As part of the Better Regulation of Medicines Initiative the notification scheme established for registering amendments to labelling and patient information leaflets will change significantly from July 2012.<br/> ]]></description>
	 </item>
 

<item>
<title>USP and BP collaboration</title>
<pubDate>Fri, 18 May 2012 14:35:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152719 </link>
	 <description><![CDATA[Following an informal harmonisation process between two major Pharmacopoeias throughout the consultative period and, with the cooperation of the manufacturer and simultaneous submissions to both the British Pharmacopoeia and the United States Pharmacopeia, new monographs for Dorzolamide Eye Drops and Dorzolamide and Timolol Eye Drops will be published in the BP 2013.<br/> ]]></description>
	 </item>
 

<item>
<title>Publication of assessment reports for European Article 45/46 paediatric work-sharing procedures - 3 May 2012</title>
<pubDate>Thu, 10 May 2012 10:40:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152639 </link>
	 <description><![CDATA[Towards the end of March and at the start of April 2012, CMDh published paediatric assessment reports following completion of three Article 45 work-sharing procedure­s.<br/> ]]></description>
	 </item>
 

<item>
<title>Monthly performance on vetting of advertising - April 2012</title>
<pubDate>Thu, 10 May 2012 09:59:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152600 </link>
	 <description><![CDATA[Details of the monthly percentage of advertising pieces submitted for vetting where the MHRA provided a response to the company within the target response time of five working days. Updated for April 2012.<br/> ]]></description>
	 </item>
 

<item>
<title>The new pharmacovigilance legislation: Information for Marketing Authorisation Holders</title>
<pubDate>Fri, 04 May 2012 16:35:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152605 </link>
	 <description><![CDATA[To support implementation of, and compliance with, the new pharmacovigilance legislation from July 2012, we have prepared some information for Marketing Authorisation Holders.<br/> ]]></description>
	 </item>
 

<item>
<title>Supply of medicines by pharmacy to healthcare professionals</title>
<pubDate>Fri, 04 May 2012 15:45:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152604 </link>
	 <description><![CDATA[This note provides guidance for pharmacists working in registered  pharmacies and in hospitals on how the MHRA, as the regulator responsible for the enforcement of EU legislation, proposes to address the implications of the necessary repeal of Section 10(7) for the supply of licensed medicines by pharmacy other than direct to the public.<br/> ]]></description>
	 </item>
 

<item>
<title>Concept paper on unique identifier for medicinal products for human use and its verification</title>
<pubDate>Tue, 01 May 2012 15:24:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON152582 </link>
	 <description><![CDATA[We have published the UK government's response to the European Commission's Concept Paper on the delegated act on the detailed rules for a unique identifier for medicinal products for human use and its verification, and a covering letter addressed to the European Commission.<br/> ]]></description>
	 </item>
 

<item>
<title>Reduced fee for Decentralised Procedure applications where the UK is the Reference Member State</title>
<pubDate>Mon, 30 Apr 2012 11:30:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON149846 </link>
	 <description><![CDATA[Under the MHRA’s new fees from 1 April 2012 we have reduced our Decentralised applications where the UK is the Reference Member State by 10 percent.<br/> ]]></description>
	 </item>
 

<item>
<title>Complaints about advertising of medicines - 27 April 2012</title>
<pubDate>Mon, 30 Apr 2012 08:34:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON149852 </link>
	 <description><![CDATA[We have published the results of four investigations into the advertising of medicines.<br/> ]]></description>
	 </item>
 

<item>
<title>Monthly performance on vetting of advertising - March 2012</title>
<pubDate>Thu, 19 Apr 2012 15:05:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON149755 </link>
	 <description><![CDATA[Details of the monthly percentage of advertising pieces submitted for vetting where the MHRA provided a response to the company within the target response time of five working days. Updated for March 2012<br/> ]]></description>
	 </item>
 

<item>
<title>Draft Blue Guide Third Edition published</title>
<pubDate>Tue, 10 Apr 2012 14:55:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON149608 </link>
	 <description><![CDATA[A draft of the Third Edition of the MHRA Blue Guide, Advertising and Promotion of Medicines in the UK, is published today.  This new edition updates our guidance on advertising medicines in a number of areas, including providing information  before the grant of a marketing authorisation and using digital communications.<br/> ]]></description>
	 </item>
 

<item>
<title>British Pharmacopoeia Commission proposes changes to inhaled product monographs</title>
<pubDate>Tue, 03 Apr 2012 14:31:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON149611 </link>
	 <description><![CDATA[The British Pharmacopoeia Commission has proposed changes to inhaled product monographs as described in the following draft policy document.<br/> ]]></description>
	 </item>
 

<item>
<title>MHRA reminder of Article 23a obligations and the ‘Sunset Clause’</title>
<pubDate>Tue, 03 Apr 2012 13:58:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON149615 </link>
	 <description><![CDATA[The purpose of this update is to remind to companies of their obligations under Article 23a of Directive 2001/83/EC, to notify the MHRA of the marketing status of their products.<br/> ]]></description>
	 </item>
 

<item>
<title>MHRA introduces more flexibility for the submission format of labels and patient leaflets</title>
<pubDate>Mon, 02 Apr 2012 15:25:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146893 </link>
	 <description><![CDATA[Following consultation with medicines trade associations and member companies we are pleased to announce some procedural changes concerning the requirement to submit full-colour mock-ups of labels and patient leaflets.<br/> ]]></description>
	 </item>
 

<item>
<title>Complaints about advertising of medicines - 26 March 2012</title>
<pubDate>Tue, 27 Mar 2012 09:20:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146858 </link>
	 <description><![CDATA[The MHRA have published the results of three investigations into the advertising of medicines.<br/> ]]></description>
	 </item>
 

<item>
<title>Publication of assessment reports for European Article 45/46 paediatric work-sharing procedures - 19 March 2012</title>
<pubDate>Mon, 19 Mar 2012 16:56:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146754 </link>
	 <description><![CDATA[Towards the end of February and at the start of March 2012, CMDh published paediatric assessment reports following completion of fourteen Article 45 work-sharing procedures.<br/> ]]></description>
	 </item>
 

<item>
<title>Letters to be sent out to customers with unpaid and overdue invoices</title>
<pubDate>Thu, 15 Mar 2012 10:13:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146691 </link>
	 <description><![CDATA[From Monday 19 March, MHRA Finance will be sending out letters to customers with unpaid and overdue invoices.  After this date, you will receive two letters in quick succession.  These initial letters will detail all invoices that MHRA consider outstanding and payable.  You will then receive periodic reminders following the generation of invoices.<br/> ]]></description>
	 </item>
 

<item>
<title>Monthly performance on vetting of advertising - February 2012</title>
<pubDate>Fri, 09 Mar 2012 14:50:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146586 </link>
	 <description><![CDATA[Details of the monthly percentage of advertising pieces submitted for vetting where the MHRA provided a response to the company within the target response time of five working days. Updated for February 2012<br/> ]]></description>
	 </item>
 

<item>
<title>European Medicines Agency publishes updated set of mandatory Article 57(2) requirements for marketing authorisation holders</title>
<pubDate>Tue, 06 Mar 2012 12:07:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146517 </link>
	 <description><![CDATA[The European Medicines Agency has published an updated set of mandatory requirements for marketing authorisation holders to comply with Article 57(2), one of the key measures of the new pharmacovigilance legislation. The mandatory data set must be submitted by 2 July 2012.<br/> ]]></description>
	 </item>
 

<item>
<title>Complaints about advertising of medicines - 5 March 2012</title>
<pubDate>Mon, 05 Mar 2012 11:17:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON146495 </link>
	 <description><![CDATA[The MHRA have published the results of two investigations into the advertising of medicines.<br/> ]]></description>
	 </item>
 

<item>
<title>MHRA meets life sciences strategy commitment to highlight to SMEs existing regulatory tools to support patient access to innovative breakthrough products</title>
<pubDate>Mon, 05 Mar 2012 11:06:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON143800 </link>
	 <description><![CDATA[We have created content on our website to meets the commitment set out in the  life sciences strategy to highlight to SMEs existing regulatory tools to support patient access to innovative breakthrough products.<br/> ]]></description>
	 </item>
 

<item>
<title>MHRA fees proposals from 1 April 2012</title>
<pubDate>Mon, 27 Feb 2012 11:01:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON143755 </link>
	 <description><![CDATA[This page provides an update on MHRA fees proposals from l April 2012.<br/> ]]></description>
	 </item>
 

<item>
<title>Annual report on regulation of medicines advertising published</title>
<pubDate>Fri, 24 Feb 2012 10:48:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON143737 </link>
	 <description><![CDATA[The MHRA has today published a sixth annual report 'Delivering high standards in medicines advertising regulation'.  This covers the year 2011.<br/> ]]></description>
	 </item>
 

<item>
<title>Change to Yellow Card website URL</title>
<pubDate>Mon, 20 Feb 2012 15:53:00 UTC</pubDate>
<link>http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON143653 </link>
	 <description><![CDATA[Further to instruction issued by the Cabinet Office on government websites, the Yellow Card website URL has been changed to www.mhra.gov.uk/yellowcard. This is in line with government policy to reduce the number of government domains.<br/> ]]></description>
	 </item>
</channel>
</rss>
<!-- the HEAD element is required by SiteStudio
	<head><script language="JavaScript">
   var _U = "undefined";
   var g_HttpRelativeWebRoot = "/home/";
   var SSContributor = false;
   var SSForceContributor = false;
   var SSHideContributorUI = false;
   var ssUrlPrefix   = "/";
   var g_navNode_Path = new Array();
       g_navNode_Path[0] = '5';
       g_navNode_Path[1] = '338';
       g_navNode_Path[2] = '100806';
       g_navNode_Path[3] = '100858';
   var g_ssSourceNodeId = "100858";
   var g_ssSourceSiteId = "5";
   var g_strLanguageId = "en";
</script>
<script id="SSNavigationFunctionsScript" language="javascript" type="text/javascript" src="/home/websites/5/sitenavigationfunctions.js"></script>
<script id="SSNavigationScript" language="javascript" type="text/javascript" src="/home/websites/5/sitenavigation.js"></script>

	<script type="text/javascript" src="/home/resources/wcm/sitestudio/wcm.toggle.js"></script>
	<script type="text/javascript" src="/home/resources/sitestudio/ssajax/ssajax.js"></script>

	</head>
-->


